Bildkälla: Stockfoto

Bioinvent Q1: In a good position - Redeye

Redeye believes the progress in Q1 has strengthened BioInvent’s position further ahead of the crucial clinical inflection point for the lead candidate BI-1206 later this year.

Redeye believes the progress in Q1 has strengthened BioInvent’s position further ahead of the crucial clinical inflection point for the lead candidate BI-1206 later this year.
Börsvärldens nyhetsbrev
ANNONSER